secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0000950170-25-037125
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus reports FY2024 net loss $85M; Phase 2 gMG top-line on track for 2H'25
------------------------------------------------------------------------------

- Net loss of $85.0M ($2.55 per share) in FY2024, vs $43.6M ($8.45 per share) in FY2023.
- Cash, cash equivalents and investments of $357.0M as of Dec 31, 2024, providing runway into 2H'27.
- R&D expenses rose to $83.1M from $32.8M, driven by clinical and CMC costs for DNTH103.
- Phase 2 MaGic gMG trial on track for top-line results in 2H'25; Phase 3 CIDP interim analysis in 2H'26.
- Appointed John C. King as CCO and Sujay Kango to Board on March 5, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/0000950170-25-037125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/dnth-20250311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-037125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer